• Mononuclear cells were collected by leukapheresis and then monocytes were separated by elutriation or adherence to a plastic surface.
• Harvested monocytes were cultivated with IL-4 and GM-CSF and differentiated into DC.
• Immature DCs were subsequently exposed to autologous tumor lysate antigens.
• Maturation was induced by lipopolysaccharide and interferon-y.
DC-based IMP was administered intradermally (ID) every 3 ± 1 weeks, up to 35 doses to a predefined site on the left or right arm near the axillary lymph node. Administration of topical Imiquimod before and 2 evenings after vaccination in the injection site. Each dose of DC is 2×106.
• No immune or infection-related AESIs were reported for all patients.
• 1 patient with Ewing sarcoma achieved complete remission (CR) Karnofsky 100.
• 3 patients achieved partial response (PR).
• 1 with Ewing sarcoma (Karnofsky 100).
• 1 with Alveolar Rhabdomyosarcoma (Karnofsky 80).
• 1 with Embryonal Rhabdomyosarcoma (Karnofsky 70).
• 1 patient with Osteosarcoma achieved stable disease (SD) (Karnofsky 90).
• 4 patients with progressive disease (PD).
Anticancer DC vaccination could be more effective if appropriately personalized not only in terms of loading DC with self- tumor antigens but also in terms of selection of the right patients that would benefit from ITx (such as patients with tumor with high mutational load), and treatment at the right time when the disease and the level of immune suppression is minimal, and selection of right (possibly personalized) concomitant treatment that allows the optimal immunostimulant and anticancer activity of effector cells. In this study shows that DC immunotherapy is effective and shows clinical outcomes in patients with Ewing sarcoma.
Article Reference link: click here
Scientific article publishing date 14/11/2019
Immucura identifier BSC21_039EN